MD Global Health

Free FedEx Ground shipping on every U.S. order · Authorized Charder distributor · Questions? Contact us
GLP-1 · Body composition

GLP-1 Medications and Body Composition: Is Your Patient Losing Fat or Muscle?

The scale shows how much weight a patient on semaglutide or tirzepatide is losing. It cannot show what that weight is made of.

GLP-1 Medications and Body Composition: Is Your Patient Losing Fat or Muscle?
On this page
  1. Not everything that comes off the scale is fat
  2. What the studies show
  3. Signs worth mentioning to your doctor
  4. Questions to ask
  5. For clinicians: what to measure

GLP-1 · Body composition

The scale shows how much weight a patient on semaglutide or tirzepatide is losing. It cannot show what that weight is made of.

MD Global Health · For patients and clinicians · 5 min read

Key points
  • A kilogram of fat and a kilogram of muscle weigh the same: body weight alone cannot tell them apart.
  • DXA sub-studies show that part of the weight lost with GLP-1–based medications is lean mass, with wide individual variation.
  • Measuring body composition, and ideally strength, helps each patient know what is actually happening in their own case.

Patients using medications such as Ozempic, Wegovy, Saxenda, Mounjaro or Zepbound often check the scale every day. That makes sense: watching the number go down feels like proof that treatment is working. But the scale has a blind spot. It does not distinguish between fat, muscle and water.

Not everything that comes off the scale is fat

The body is made mainly of fat, muscle and water. Whenever weight drops quickly, whether through diet, bariatric surgery or medication, some muscle is lost along with fat. This is not unique to GLP-1 medications, but because they produce faster and larger weight loss than most diets, clinicians have paid much closer attention to lean mass over the last two years.

What the studies show

Using DXA, researchers have measured what share of the weight lost with each medication was lean mass:

MedicationOf every 10 kg lost, approximately this much was lean mass
Semaglutide (Ozempic, Wegovy)2.5 to 4 kg
Liraglutide (Saxenda)Up to 6 kg
Tirzepatide (Mounjaro, Zepbound)2.5 to 3 kg

Table 1. Approximate figures calculated from the percentages reported in published DXA sub-studies. Lean mass includes muscle, organs and water; results vary widely between individuals.

These numbers are not meant to alarm. Losing some lean mass alongside fat is expected with substantial weight loss by any method. The open question researchers are studying is whether that loss translates into weakness or reduced function, or is simply part of the process without major consequence. That is exactly why measuring the individual patient matters more than the average.

Signs worth mentioning to your doctor

None of these alone means something is wrong, but if several appear while losing weight, bring them up at the next visit:

  • Feeling more tired or weaker than usual in daily life.
  • More difficulty climbing stairs, carrying groceries or getting up from a low chair.
  • Weaker hands, for example when opening a jar or bottle.
  • Losing weight very fast while doing little exercise or eating little protein.

Questions to ask

  • Is my muscle being monitored during treatment, or only my weight?
  • How often should we check it?
  • What can I change in my diet or routine if I am losing more muscle than expected?
  • Does the clinic have equipment to measure this?

For clinicians: what to measure

Segmental bioimpedance makes body-composition tracking practical at every visit: fast, radiation-free and repeatable under the same conditions. Analyzers such as the Charder MA601 and MA801 report fat mass, skeletal muscle and segmental lean mass, and a grip-strength dynamometer adds the functional side. Comparing each patient with themselves over time, on the same device and protocol, is what makes the data meaningful.

Track fat and muscle, not just weight

Free U.S. shipping, 30-day returns and technical support from an authorized Charder distributor.

Body composition analyzersRequest a quote
Sources

Based on studies published between 2024 and 2026, including the SEMALEAN study, the STEP UP trial (Lancet Diabetes & Endocrinology, 2025), the SURMOUNT-1 body-composition sub-study, a review in Circulation (2024) and a 2026 meta-analysis on GLP-1 therapy and body composition.

This article is for information only and does not replace personalized medical advice. Do not start, change or stop any treatment without talking to your doctor.

Continue reading

All articles
For clinics & health systems

Bring objective measurement to your practice

Charder body composition analyzers, medical scales, stadiometers and dynamometers — FDA registered, free U.S. shipping and a 12-month warranty.

Join Waitlist We will inform you when the product arrives in stock. Please leave your valid email address below.